Skip to main content
. 2013 May 16;8(5):e63966. doi: 10.1371/journal.pone.0063966

Figure 3. DTCD increases DR5 but not DR4 levels in ovarian cancer cell lines.

Figure 3

(A) DTCD-induced DR5 upregulation in A2780 cells. Cells were treated with 10 µM DTCD for the indicated time or treated with indicated amount of DTCD for 24 h and then subjected to Western blot analysis. (B) Effects of DTCD on the surface expression levels of DR5. Cells were incubated with or without 10 µM DTCD for 24 h, then subjected to flow cytometry analysis. (C) DTCD-induced DR5 upregulation in other types of ovarian cancer cells. (D) Effect of DR5 siRNA on DTCD/TRAIL-induced cell death. A2780 cells were transfected with control siRNA or DR5 siRNA. 24 h after the transfection, cells were treated with 10 µM DTCD and 200 ng/mL TRAIL for another 24 h. Cellular viability was determined by MTT assay (left). The levels of DR5 were analyzed by Western Blotting (right). *, P<0.05 versus vehicle control.